News | October 12, 2008

Online Conference Presents Latest Advances in Breast Cancer Patient Care

October 13, 2008 - A nationally recognized faculty will present the very latest treatment strategies for patients with breast cancer in the multimedia course “Optimizing Adjuvant Breast Cancer Strategies: From Biomarkers to Treatment Selection” during National Breast Cancer Awareness Month.

This accredited course offers concise, expert reporting on key, practical treatment innovations, including research from recent American Society of Clinical Oncology (ASCO) annual meetings and San Antonio Breast Cancer Symposia. Highlights of the meeting include:

- Program Chair Antonio C. Wolff, MD, FACP, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will discuss biomarkers

- Harold J. Burstein, M.D., Ph.D., from the Breast Oncology Center, the Dana-Farber Cancer Institute, and Harvard Medical School, will present on recent developments in chemotherapy-biologic treatments.

- Ana Maria Gonzalez-Angulo, M.D., MSc, of The University of Texas M. D. Anderson Cancer Center, will discuss the issue anthracycline related cardiotoxicity

Physicians can register for and take this accredited, virtual e-conference course at any time beginning Tuesday, Oct. 14, 2008, at www.virtualbreastcancer.com. Participants learn at their own pace and utilize interactive case studies, choosing treatments for simulated patients and receiving feedback on their decisions.

The faculty will offer a “Live Question-and-Answer Session” on Oct. 14, 2008, from 12:00-2:00 p.m. (EDT). The course, including faculty presentations and questions and answers generated on Oct. 14, will remain available for one year.
The course is presented by The Johns Hopkins University School of Medicine in cooperation with PharmacoMedia LLC, and is supported by an educational grant from sanofi-aventis U.S. It is available at no cost to participants.

For more information: www.virtualbreastcancer.com

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init